Trial Profile
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peficitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Astellas Pharma
- 16 Oct 2016 Results published in the Arthritis and Rheumatology.
- 25 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 27 Dec 2013 Planned End Date changed from 1 Aug 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.